



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
WASHINGTON, D.C. 20555-0001

December 17, 2013

Mr. Robin DeLaBarre  
Office of Nuclear Energy,  
Safety & Security Affairs, Room 3320 HST  
Bureau of International Security  
& Nonproliferation  
U.S. Department of State  
2201 C Street, NW  
Washington, D.C. 20520

Dear Mr. DeLaBarre:

Enclosed is an application (XMAT431), dated August 29, 2013, received by the U.S. Nuclear Regulatory Commission (NRC), from Concert Pharmaceuticals, Inc. for the export of up to 20,000 kilograms of heavy water (D<sub>2</sub>O) over a five-year period to Hovione FarmaCiencia SA in Portugal and DSM Fine Chemicals Austria Nfg GmbH & Co KG in Austria for a non-nuclear end use in active pharmaceutical ingredient manufacturing.

Inasmuch as Executive Branch views are not required for exports of deuterium to EURATOM for a non-nuclear end-use, the NRC intends to issue the requested license after the required 30-day waiting period is complete upon the publication of notice in the Federal Register.

Sincerely,

A handwritten signature in blue ink, appearing to read "Brooke G. Smith".

Brooke G. Smith, Branch Chief  
Export Controls and International Organizations  
Office of International Programs

Enclosure:  
Application Dated 8/29/2013  
XMAT431 – Portugal and Austria  
Docket Number 11006131

cc w/enclosure:  
Foreign Obligations, NRC/NMSS  
J. Norles, DOE/NNSA  
P. Dessaulles, DOE/NMMSS  
S. Clagett, DOC

R. Goorevich, DOE/NNSA  
K. Strangis, DOE/NNSA  
C. Baugues, DHS/CBP  
E. Sauls, DTRA